An Invivo Study to Compare the Stability of Dental Implants With or Without Platelet Rich Fibrin Application
Launched by ELİF ONCU · Jul 14, 2014
Trial Information
Current as of May 14, 2025
Completed
Keywords
ClinConnect Summary
Objectives:Achieving accelerated implant osseointegration could provide immediate or early loading of implants. Platelet-rich fibrin (PRF) is widely used to accelerate soft and hard tissue healing. Activated platelets in PRF release growth factors resulting in cellular proliferation, collagen synthesis and osteoid production. The aim of this study was to compare the stability of dental implants inserted with one-stage surgical protocol with or without PRF application.
Design: Non-randomized, Active Controlled Trial. Material and Methods: Twenty healthy patients (n=10 test group, n= control...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • The absence of any lesions in the oral cavity, and sufficient residual bone volume to receive two or more adjacent implants of ≥3.5 mm in diameter and 11.0 mm in length, and extracted at least 6 months ago.
- Exclusion Criteria:
- • Insufficient bone volume
- • Parafunctional habits
- • Smoking more than 10 cigarettes per day
- • Excessive consumption of alcohol
- • Localized radiotherapy of the oral cavity
- • Antitumor chemotherapy
- • Liver, blood, and kidney diseases
- • Immunosuppression
- • Current corticosteroid or bisphosphonate use
- • Pregnancy
- • Mucocutaneous diseases involving oral cavity
- • Poor oral hygiene
About Eli̇f Oncu
Elif Oncu is a dedicated clinical trial sponsor committed to advancing medical research and innovation. With a focus on developing effective therapeutic solutions, Elif Oncu collaborates with leading research institutions and healthcare professionals to design and execute clinical trials that adhere to the highest ethical and scientific standards. Through meticulous planning and robust data management, the organization strives to contribute valuable insights to the medical community, ultimately enhancing patient care and outcomes. Elif Oncu's expertise in trial management and regulatory compliance positions it as a trusted partner in the pursuit of groundbreaking healthcare advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ankara, , Turkey
Patients applied
Trial Officials
ELİF ÖNCÜ, 1
Principal Investigator
NECMETTİN ERBAKAN UNIVERSITY
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials